Equivalent outcomes in nasal symptoms following microscopic or endoscopic transsphenoidal surgery: results from multi-centre, prospective study

Charlie Osborne1,2 · Daniel Lewis2 · Ben Dixon3 · Carmela Caputo4 · Alison Magee5 · Kanna Gnanalingham2 · Yi Yuen Wang1,2,5

Received: 9 February 2021 / Accepted: 2 January 2022 / Published online: 8 February 2022 © The Author(s) 2022

Abstract

Background Transsphenoidal surgery (TSS) is the standard approach for resection of pituitary lesions. Historically, this has utilized the microscopic approach (mTSS); however, the past decade has seen widespread uptake of the endoscopic approach (eTSS). The purported benefits of this include improved visualization and illumination, resulting in improved surgical and endocrinological patient outcomes. It is also believed that eTSS results in fewer post-operative nasal symptoms compared to mTSS; however, few papers have directly compared these groups.

Objectives We sought to compare nasal symptoms after endoscopic uninostril (eTSS-uni), endoscopic binostril (eTSS-bi) and microscopic endoscopic transsphenoidal surgery (mTSS).

Methods The General Nasal Patient Inventory (GNPI) was prospectively administered to 136 patients (71 non-functioning adenomas, 26 functioning adenomas, 39 other pathology) undergoing transsphenoidal surgery at multiple time points (pre-operatively; days 1, 3 and 7–14; months 1, 3 and 6 and 1 year post-operatively). All surgeries were performed by subspecialist pituitary surgeons in three subgroups — mTSS (25), eTSS-uni (74) and eTSS-bi (37). The total GNPI scores (0–135) and subscores for the 45 individual components were compared across three groups assessing for temporal and absolute changes.

Results Irrespective of surgical approach used, GNPI scores were significantly higher on post-operative day 1 (p < 0.001) and day 3 (p ≤ 0.03) compared to pre-treatment baseline (mixed-effects model). By 1 month post-operatively, however, post-operative GNPI scores were no different from pre-treatment (p > 0.05, mixed-effects model). Whilst the eTSS-uni group demonstrated significantly lower GNPI scores at day 1 post-op compared to the mTSS group (p = 0.05) and eTSS-bi group (p < 0.001), there was no significant difference in post-operative scores between approaches beyond 1–2 weeks post-operatively. Similar results were obtained when the non-functioning tumour group was analysed separately.

Conclusions Transsphenoidal pituitary surgery is well tolerated. Post-operative nasal symptoms transiently worsen but ultimately improve compared to pre-operative baseline. Operative approach (microscopic, endoscopic uninostril or endoscopic binostril) only has a transient effect on severity of post-operative nasal symptoms.

Keywords Nasal symptoms · Transsphenoidal surgery · Endoscopic · Microscopic
Abbreviations
TSS Transsphenoidal surgery
mTSS Microscopic transsphenoidal surgery
eTSS Endoscopic transsphenoidal surgery
eTSS-uni Endoscopic uninostril transsphenoidal surgery
eTSS-bi Endoscopic binostril transsphenoidal surgery

Introduction
Endoscopic transsphenoidal surgery (eTSS) is increasingly becoming the standard approach for resection of pituitary lesions [6, 20]. Compared to the traditional microscopic transsphenoidal approach (mTSS), the endoscope is reported to afford greater visibility allowing for more extensive dissection and higher rates of gross tumour resection [1, 22, 28]. The endoscopic approach typically affords shorter operative time and reduced length of stay with comparable, if not improved, rates of post-operative complications across the two modalities [5]. Specifically, a lower rate of nasal symptoms including anosmia, septal perforations and epistaxis is described [7, 9, 17, 18, 24].

Regardless of the surgical approach, patients who undergo TSS often develop post-operative nasal symptoms such as pain, congestion, discharge, bleeding and altered or unpleasant tastes or smells. Previously, we have used the General Nasal Patient Inventory (GNPI), a 45-item patient-derived validated questionnaire, to assess the temporal changes in nasal symptoms following eTSS for pituitary lesions [3, 27]. Following eTSS, nasal symptoms typically develop early in the post-operative course and tend to resolve by a few weeks post-operatively [27]. Overall, the surgery is well tolerated and, despite a transient exacerbation, the post-operative nasal symptoms also improve when compared to pre-operative baseline [2].

In considering nasal complications following TSS, whilst several centres report on the incidence of defined anatomical complications (e.g., epistaxis and septal perforations), few papers have assessed the functional effects of nasal complications through the administration of patient-reported sinonasal QOL questionnaires [7, 16, 19, 21]. Such patient-based questionnaires are increasingly being validated for use as outcome measures, providing individualized evaluation of the success of a given therapy.

The GNPI is a sensitive tool used in assessing pre- and post-operative nasal symptoms following nasal intervention [3]. In this prospective study, we used the GNPI with the aim of comparing nasal symptoms across surgical groups of patients undergoing either eTSS or mTSS to clarify if any differences exist.

Methods
One hundred and thirty-six consecutive adult patients undergoing transsphenoidal pituitary surgery over an 18-month period (January 2015 to August 2016) were prospectively enrolled into the study. Surgery was performed by subspecialist pituitary neurosurgeons (two endoscopic and one microscopic) across three centres. All patients had been listed for surgery after an institutional multi-disciplinary meeting. Patient demographics including clinical presentation, MR imaging findings, endocrine profile, operative details, complications and tumour pathology were noted.

Patients either underwent a microscopic approach, endoscopic uninostril approach (eTSS-uni) or endoscopic binostril approach (eTSS-bi), depending on surgeon’s preference and type of pathology (e.g., binostril approaches for larger tumours and for non-adenomatous lesions requiring extended transsphenoidal approaches).

Operative technique
Both operative techniques have been well described previously and are summarized here [8, 13, 29]. All patients received broad spectrum peri-operative antibiotics with anaerobic cover.

Microscopic
Nasal preparation was performed with injection of vasoconstrictor (lignocaine/adrenaline 1:100,000) into the right nasal septum and antiseptic betadine wash performed with pre-operative packing with betadine-soaked nasal ribbons. A single nostril approach is utilized with gradual expansion of the nasal cavity with nasal speculums resulting in lateralization of the middle turbinate and a posterior fracture of the bony nasal septum. In this manner, posterior nasal mucosa is opened directly and the sphenoid ostia identified. A wide unified sphenoidotomy is performed to expose the sella floor. The sphenoid mucosa is reflected laterally to allow access to the pituitary proper and tumour resection performed.

Closure following tumour removal involves inspection of the cavity to identify significant mucosal bleeding points, which are controlled with diathermy. The nasal speculum is removed and the deflected middle turbinate and nasal septum are medialized. Nasal packing is not routinely employed post-operatively and no nasal decongestant is prescribed.

Endoscopic
Nasal preparation is performed with topical applications of pre-operative decongestants (cophenylcaine, Aurum Ltd.) and injection of vasoconstrictor (lignocaine/adrenaline
The patients had to select from 4 numerical answers (0–135) for each of the 45 items, assessing nasal symptoms across eight time points: pre-operatively, days 1, 3 and 7–14 post-operatively and months 1, 3, 6 and 12 months post-operatively. For each of the 45 items, total scores (0–135) for each patient and individual scores for each item were recorded and analysed allowing assessment of global as well as specific changes in nasal symptoms over time. An overview of each item included within the GNPI questionnaire is provided in supplementary table S1. Approval for the study was obtained from the local institutional review board and all patients consented to participate in the study.

**Statistical analysis**

Stata version 11 and the SPSS statistical software package (version 25, IBM Corp.) were used for all statistical analyses. Descriptive results are presented as medians (interquartile ranges) and frequency (percentage). Differences in patient age and total GNPI score between different surgical groups were evaluated using the Kruskal–Wallis test with post hoc analysis of pairwise comparisons using the Bonferroni method. Differences in categorical variables (patient gender, tumour histology, tumour size, use of nasoseptal flap, prior endonasal surgery intra-operative CSF leak and post-operative meningitis/sinusitis) between groups were determined using Pearson’s chi-square test. To evaluate differences in total GNPI score at each time point between non-functioning pituitary adenomas (NFPAs) and functioning adenomas, the Mann–Whitney U test was used.

Changes in total GNPI score over time were analysed using a repeated measures mixed-effects model with imaging time point as a fixed-effects variable. Post hoc analysis of pairwise comparisons between different time points was performed using the Bonferroni method. Ordinal logistic regression was used to evaluate the effect of patient demographics (age, gender), surgical approach, tumour histology and tumour size on the total GNPI score pre-treatment and at post-operative days 1 and 3. Results are presented as odds ratios with 95% confidence intervals. In addition to comparison of total GNPI scores, the percentage of asymptomatic patients (score = 0) for each individual symptom question was reported and scores compared across each time point using Pearson’s chi-square test.

**Results**

**Population characteristics and pathological data**

There was no gender preponderance (female = 68; 50%). Median age of enrolled patients was 57.7 (IQR 44.5–70.0). Pituitary adenomas were the predominant pathology, present in 97 patients (71%) with remaining tumours as follows: 19 cystic lesions (14 Rathke’s cleft cyst and 5 craniopharyngiomas), 6 meningiomas and 14 miscellaneous (pituitary apoplexy, cholesterol granuloma, chordoma, lymphocytic hypophysitis, lymphoma, myeloma and Wegener’s granulomatosis). The majority of patients (N = 71; 52%) were diagnosed with NFPAs. The majority of lesions were macro adenomas (N = 83; 61%) with functioning tumours accounting for 19% (N = 26).

There were three subgroups based on surgical approaches used: 25 (18%) mTSS, 74 (54%) eTSS-uni and 37 (27%) eTSS-bi. Within the eTSS-uni approach group, three patients...
had undergone prior endonasal surgery for a NFPA. There were no revision surgeries within either the mTSS or eTSS-bi approach groups.

Intra-operative CSF leak was noted in 36% with no significant difference across either surgical groups (p > 0.05, chi-square test, Table 1). Repair of intra-operative CSF leak followed a graded repair utilizing non-vascularized autologous grafting and synthetic buttressing for low-grade leaks, and vascularized nasoseptal flaps for high-grade leaks [27]. No patients suffered from a post-operative CSF leak.

A nasoseptal flap repair was utilized significantly more in the eTSS-bi subgroup (p < 0.001, chi-square test). All 4 patients (100%) undergoing nasoseptal flap repair in the eTSS-uni group had documented intra-operative CSF leak compared to 2 patients (50%) in the mTSS group and 12 patients (80%) in the eTSS-bi group. There was a significant difference in the presenting pathology of patients undergoing nasoseptal repair (p < 0.001, chi-square test) with 5/6 patients undergoing meningioma resection requiring nasoseptal flap repair compared to only 7/71 patients with NFPA and 1/26 patients undergoing surgery for functioning tumours, respectively. After undergoing the eTSS-uni approach, two patients (1%) developed post-operative meningitis and three patients (2%) developed sinusitis. There were no cases of meningitis/sinusitis following either the mTSS or eTSS-bi approach but these differences between approaches were not statistically significant (p > 0.05, chi-square test).

### Changes in GNPI scores over time

Changes in total GNPI score across all 136 patients are shown in Fig. 1a. Irrespective of surgical approach, total GNPI scores were significantly higher at post-operative day 1 (p < 0.001) and day 3 (p ≤ 0.03) compared to pre-treatment scores (mixed-effects model). Post-operative GNPI scores at 1 month post-operatively were no different from pre-treatment (p > 0.05, mixed-effects model). In both the eTSS-uni and eTSS-bi groups, total GNPI was significantly lower at 6 months (p ≤ 0.02) and 12 months (p ≤ 0.03) compared to pre-treatment. Whilst scores at 6 months and 12 months in the mTSS group were also lower than pre-treatment, this difference was not statistically significant (p > 0.05, mixed-effects model).

The eTSS-uni group demonstrated significantly lower GNPI scores at day 1 post-op compared to the mTSS group (p = 0.05) and eTSS-bi group (p < 0.001, Kruskal–Wallis test, Fig. 1b) but by weeks 1–2, this effect had disappeared. This difference in early (day 1) post-treatment GNPI scores between approaches was maintained even after exclusion of the six patients undergoing meningioma resection (supplementary Fig. S1). Exclusion of patients undergoing

### Table 1 Population characteristics and pathological data stratified by surgical approach

| Factor                      | Total (%) | Microscopic TSS | Uninostril eTSS | Binostril eTSS | p value |
|-----------------------------|-----------|-----------------|-----------------|----------------|---------|
| N                           | 136       | 25              | 74              | 37             | 0.99    |
| Median age, years (IQR)     | 57.7 (44.5–70.0) | 54.4 (47.9–66.3) | 59.4 (43.1–68.5) | 57.0 (44.6–73.7) | 0.02    |
| Gender                      |           |                 |                 |                |         |
| Male                        | 68 (50)   | 11 (44)         | 37 (50)         | 20 (54)        | 0.74    |
| Female                      | 68 (50)   | 14 (66)         | 37 (50)         | 17 (46)        |         |
| Histology                   |           |                 |                 |                |         |
| NFPA                        | 71 (52)   | 9 (36)          | 46 (62)         | 16 (43)        | 0.02    |
| Functioning (ACTH/GH/PRL)   | 26 (19)   | 5 (20)          | 14 (19)         | 7 (19)         |         |
| Meningioma                  | 6 (4)     | 0 (0)           | 1 (1)           | 5 (14)         |         |
| RCC                         | 14 (10)   | 4 (16)          | 8 (11)          | 2 (5)          |         |
| Cranioopharyngioma          | 5 (4)     | 2 (8)           | 1 (1)           | 2 (5)          |         |
| Other*                      | 14 (10)   | 5 (20)          | 4 (5)           | 5 (14)         |         |
| Tumour size                 |           |                 |                 |                |         |
| Macroadenoma                | 83 (61)   | 11 (44)         | 52 (70)         | 20 (54)        | 0.08    |
| Microadenoma                | 14 (10)   | 3 (12)          | 8 (11)          | 3 (8)          |         |
| Non-adenoma                 | 39 (29)   | 11 (44)         | 14 (19)         | 14 (38)        |         |
| Use of septal flap          | Yes       | 23 (17)         | 4 (16)          | 4 (5)          | <0.001  |
| Prior endonasal surgery     | Yes       | 3 (2)           | 0 (0)           | 3 (4)          | 0.28    |
| Intra-op CSF leak           | Present   | 49 (36)         | 5 (20)          | 29 (39)        | 0.18    |

*Other = apoplexy; cholesterol granuloma; chordoma; lymphocytic hypophysitis; lymphoma; myeloma; Wegener’s granulomatosis

ACTH, corticotropinoma; eTSS, endoscopic transsphenoidal surgery; GH, somatotropinoma; IQR, interquartile range; NFPA, non-functioning pituitary adenoma; PRL, prolactinoma; RCC, Rathke’s cleft cyst; eTSS, endoscopic transsphenoidal surgery

Other = apoplexy; cholesterol granuloma; chordoma; lymphocytic hypophysitis; lymphoma; myeloma; Wegener’s granulomatosis
nasoseptal flap repair led to lower immediate (days 1 and 3) post-operative scores in all groups and lower scores at 6 months and 1 year in the eTSS-bi group (supplementary Fig. S2).

Within the NFPA (N = 71) subgroup, total GNPI scores were significantly higher than pre-treatment scores at post-operative day 1, day 3 and 1–2 weeks post-operatively and were significantly lower than pre-treatment scores at 6 months and 12 months post-treatment (mixed-effects model). **p ≤ 0.01; ***p ≤ 0.001. b Change in total GNPI score stratified by surgical approach. A value for microscopic TSS/binostril eTSS approach is shown and represents difference in GNPI score compared to uninostril eTSS approach at each time point. p value calculated using Kruskal–Wallis test with post hoc analysis of pairwise comparisons using the Bonferroni method. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. eTSS, endoscopic transsphenoidal surgery

As shown in supplementary table S1, the majority of GNPI items showed a significant trend with an initial drop in the percentage of asymptomatic patients (score = 0) up to 1 month post-operatively and a recovery in the percentage of asymptomatic patients close to or above pre-treatment levels by 6–12 months post-treatment (mixed-effects model, **p < 0.001).

Within the NFPA (N = 71) subgroup, total GNPI scores were significantly higher than pre-treatment scores at post-operative day 1 (p < 0.001) and day 3 (p < 0.001) and significantly lower than pre-treatment scores at 12 months post-treatment (p < 0.001, mixed-effects model, Fig. 2a). Analysis of the NFPA subgroup demonstrated that at post-operative day 1, the eTSS-uni group demonstrated lower GNPI scores compared to the mTSS group (median GNPI 16 vs 32) and eTSS-bi group (median GNPI 16 vs 33) but these results did not reach statistical significance (p > 0.05, Kruskal–Wallis test, Fig. 2b).
the percentage of asymptomatic patients at 12 months post-operatively compared to pre-treatment.

**Comparison in GNPI scores between non-functioning and functioning tumours**

Patients with functioning adenomas had higher GNPI scores at baseline (pre-treatment) compared to NFPA ($p < 0.001$, Mann–Whitney $U$ test), but by week 1, this difference has disappeared (Fig. 3). Presence of a functioning tumour was a significant predictor of higher pre-treatment GNPI (OR 3.93, $p = 0.007$) but age, gender and tumour size were not significant predictors.

Ordinal logistic regression (Table 2) demonstrated that significant independent predictors of higher GNPI at day 1 post-op were younger age (OR 0.96, $p = 0.001$), higher pre-treatment GNPI (OR = 1.08, $p < 0.001$), microscopic rather than eTSS-uni (OR 0.30, $p = 0.008$) and the use of a nasoseptal flap (OR 3.48, $p = 0.02$). There was no predictive value of a functioning tumour resulting in higher GNPI at day 1 once the higher pre-treatment GNPI is accounted for (OR 0.48, $p = 0.14$).

**Discussion**

There are few papers to directly compare nasal symptoms between established trans-nasal surgical approaches for pituitary region lesions. Previous studies focusing on singular approaches have confirmed an early increase of symptoms followed by resolution over the ensuing months. These studies utilized the GNPI or the 22-item sinonasal test (SNOT-22) investigating single-surgeon eTSS or mTSS, respectively [2, 25, 27]. The conclusions of these papers were that rhinological recovery is typically rapid and relatively complete by 3 to 4 months post-surgery [2, 4, 25, 27]. The implication of such studies was that the endoscopic approach affords a greater improvement in rhinological recovery, and this was further investigated in our study.

![Fig. 3 Total GNPI score changes over time stratified by adenoma functional status. Median and interquartile range of total GNPI score at each time point shown. $p$ value represents difference in total GNPI score between non-functioning/functioning tumours at each time point. $p$ value calculated using Mann–Whitney $U$ test. *$p \leq 0.05$; **$p \leq 0.01$; ***$p \leq 0.001$. ACTH, corticotropinoma; GH, somatotropinoma; NFPA, non-functioning pituitary adenoma; PRL, prolactinoma](image-url)

**Table 2** Ordinal logistic regression to evaluate the effect of each parameter on post-operative day 1 and day 3 GNPI score ($N = 136$)

| Variable                        | Day 1 GNPI | Day 3 GNPI |
|---------------------------------|------------|------------|
|                                 | OR 95% OR  | $p$ value  | OR 95% OR  | $p$ value  |
| Age, years                      |            |            |
| Gender                          | Female     |            |
|                                 |            |            |
| Pre-treatment GNPI              |            |            |
| Approach base: Microscopic      |            |            |
| Uninostril eTSS                 | 0.30       | 0.12, 0.72 | 0.008 | 1.123 | 0.51, 2.97 | 0.64 |
| Binostril eTSS                  | 1.09       | 0.42, 2.79 | 0.86  | 2.01  | 0.79, 5.10 | 0.14 |
| Histology base: NFPA            |            |            |
| Functioning (ACTH/GH/PRL)       | 0.48       | 0.18, 1.28 | 0.14  | 0.84  | 0.30, 2.21 | 0.74 |
| Meningioma                      | 1.34       | 0.13, 13.4 | 0.80  | 1.51  | 0.19, 12.5 | 0.70 |
| RCC                             | 0.31       | 0.06, 1.59 | 0.16  | 0.78  | 0.16, 3.66 | 0.75 |
| Cranioopharyngioma              | 0.32       | 0.04, 2.72 | 0.29  | 0.66  | 0.09, 5.15 | 0.70 |
| Other*                          | 0.14       | 0.02, 0.75 | 0.02  | 0.40  | 0.08, 2.10 | 0.28 |
| Tumour size base: microadenoma  |            |            |
| Macroadenoma                    | 0.32       | 0.08, 1.20 | 0.09  | 0.74  | 0.21, 2.64 | 0.65 |
| Use of septal flap              | Yes        |            |
|                                 | 3.48       | 1.18, 10.3 | 0.02  | 6.09  | 1.90, 19.4 | 0.002 |
| Intra-op CSF leak               | Present    |            |
|                                 | 0.70       | 0.33, 1.47 | 0.35  | 0.70  | 0.33, 1.45 | 0.33 |

*ACTH, corticotropinoma; eTSS, endoscopic transsphenoidal surgery; GH, somatotropinoma; IQR, interquartile range; NFPA, non-functioning pituitary adenoma; PRL, prolactinoma; RCC, Rathke’s cleft cyst; eTSS, endoscopic transsphenoidal surgery*
Contrary to previous reports, our study showed no differences in nasal symptoms beyond 1–2 weeks, when comparing mTSS and eTSS-uni or eTSS-bi. Eseonu et al. have reported an economic benefit in eTSS over mTSS with a trend towards decreased nasal complications [5]. Most reported complications are however anatomical issues including septal perforations, nasal adhesions and epistaxis [7, 9, 17, 18, 24]. Using patient-reported questionnaires such as the GNPI and SNOT-22, the functional impact of such anatomical issues seems to be less significant. It has also been shown that the experience of the operating surgeon results in significant improvement in endocrinological outcomes following transsphenoidal surgery [10, 12, 26]. In this study, all surgeons involved were specialist trained pituitary surgeons having a combined surgical experience of over three thousand patients. A low rhinological complication rate from the included cohort of patients is therefore expected and a limitation of this study is that the findings may not be broadly applicable to lower volume treatment centres and practitioners.

Little et al. carried out a multi-modality review of mTSS compared to eTSS [19]. No specific patient-reported outcomes were assessed in their study; however, significant differences were found in favour of mTSS with regard to duration of surgery [19]. In our experience, the endoscopic technique requires a more careful dissection of the nasal cavity to allow the passage of instruments, whilst minimizing contamination of the endoscope lens with blood and debris. This may contribute to the increased duration of surgery undertaken with an endoscope. Our observation that the early post-operative nasal symptom scores following unilateral eTSS were marginally lower compared to mTSS would imply reduced nasal trauma secondary to static retraction by the nasal speculum in mTSS [21].

Our study also revealed a sustained improvement in post-operative nasal symptoms following eTSS-uni and eTSS-bi from 6 months post-surgery compared to pre-operative nasal scores. A similar trend was seen in the mTSS group, and whilst not statistically significant, this may reflect the lower number of patients in this group. These findings agree with a recent study utilizing patient-reported outcome measures to assess nasal symptoms in patients undergoing endoscopic and microscopic approaches [21]. Pledger et al. reported significant improvement across vitality, mental and physical health, and social functioning by 1 year after surgery in both mTSS and eTSS [21]. Improvements in nasal cavity anatomy, by addressing nasal polyps and septal deviations during the nasal phase of TSS, may in part contribute to the post-operative improvement in patient-related outcome [15]. Successful treatment of the patients’ underlying condition, notably surgical cure of functioning adenomas such as in acromegaly and Cushing’s disease, may also in part explain this trend [2].

In developed countries, endoscopic transsphenoidal surgery is increasingly becoming the standard approach for resection of pituitary lesions and this is evidenced by the larger number of patients undergoing eTSS compared to mTSS in our cohort [6, 20]. Implementation of endoscopic endonasal surgery in low- and middle-income countries, however, remains challenging and a comparison of post-operative sinonasal outcomes between microscopic and endoscopic approaches is therefore still relevant. Our study demonstrates that whilst early post-operative nasal symptom scores following unilateral eTSS are lower, long-term nasal outcomes across endoscopic and microscopic approaches are comparable. Whilst there are clear surgical benefits afforded by the endoscopic technique (Refs. 3–5), this equivalence in long-term patient quality of life measures between approaches should be recognized and appraised before implementing potentially costly endoscopic techniques in resource poor healthcare settings.

One interesting finding of our study was that patients with functioning adenomas had worse patient-reported symptoms at baseline (pre-treatment) compared to those with non-functioning tumours. This may reflect the fact that some functioning tumours (e.g., somatotropinoma) present with upper-airway and nasal symptoms [1, 6, 20, 22]. In acromegaly for example, growth hormone excess can lead to hypertrophy of nasal passages and pharyngeal tissues, leading to increased nasal symptoms and sleep apnea pre-operatively [6, 22]. Excess hormone production in functioning tumours such as in Cushing’ disease has similarly been associated with reduced general quality of life indices in earlier studies [5, 28]. The post-operative improvement seen in GNPI scores in the functioning group is therefore likely to reflect reduction in excess hormone production from these tumours as well as changes in nasal anatomy following surgery [1, 6, 20, 22].

In the present study, the use of the nasoseptal flap was noted to increase the post-operative nasal symptoms in the short-term. The efficacy of the nasoseptal flap for CSF leak repair is well established [14, 23] and although 36% of subjects had an intra-operative leak noted in our study, no patients suffered from a post-operative CSF leak. The absence of post-op CSF leaks in patients with low-grade intra-operative CSF leaks managed without flaps suggests it may be safe to omit the nasoseptal flap where there is no significant dural resection [27].

**Conclusion**

Nasal symptoms following transsphenoidal surgery are mild and self-limiting regardless of surgical approach. Contrary to previous reports, the microscopic transsphenoidal approach does not result in worse long-term nasal outcomes compared
to the endoscopic approach. Transsphenoidal surgery is well tolerated regardless of approach with potential for long-term improvement in nasal function beyond 6 months post-surgery.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00701-022-05138-5.

Acknowledgements Funding provided data for a number of patients in this study.

References need to obtain permission directly from the copyright holder. To view a permitted by statutory regulation or exceeds the permitted use, you will otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated were made. The images or other third party material in this article are provided a link to the Creative Commons licence, and indicate if changes as you give appropriate credit to the original author(s) and the source, Open Access

Conflict of interest The authors declare no competing interests.

Ethics approval This study was performed in line with the principles of the Declaration of Helsinki. Approval for the study was granted by the institutional review board of St Vincent’s Hospital, Melbourne, and Salford Royal Hospital UK.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Akbari H, Malek M, Ghorbani M, Ramak Hashemi SM, Khamseh ME, Zare Mehrjardi A, Emami Z, Ebrahim Valojerdi A (2018) Clinical outcomes of endoscopic versus microscopic transsphenoidal surgery for large pituitary adenoma. Br J Neurosurg 32:206–209
2. Davies BM, Tirit E, Wang YY, Gnанalingham KK (2017) Transient exacerbation of nasal symptoms following endoscopic transsphenoidal surgery for pituitary tumors: a prospective study. J Neurol Surg B, Skull base 79:131–138
3. Fatemi N, Dusick JR, de Paiva Neto MA, Kelly DF (2008) The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience. Neurosurgery 63:244–256; discussion 256
4. Gao Y, Zhong C, Wang Y, Xu S, Guo Y, Dai C, Zheng Y, Wang Y, Luo Q, Jiang J (2014) Endoscopic versus microscopic transsphenoidal pituitary adenoma surgery: a meta-analysis. World J Surg Oncol 12:94
5. Esenou CI, ReFaey K, Garcia O, Salvatori R, Quinones-Hinojosa A (2018) Comparative cost analysis of endoscopic versus microscopic endonasal transsphenoidal surgery for pituitary adenomas. J Neurol Surg B, Skull base 79:131–138
6. Esenou CI, ReFaey K, Rincon-Torrella J, Garcia O, Wand GS, Salvatori R, Quinones-Hinojosa A (2017) Endoscopic versus microscopic transsphenoidal approach for pituitary adenomas: comparison of outcomes during the transition of methods of a single surgeon. World neurosurgery 97:317–325
7. Fang J, Xie S, Li N, Jiang Z (2018) Postoperative complications of endoscopic versus microscopic transsphenoidal pituitary surgery: a meta-analysis. J Coll Phys Surgeons-Pakistan 28:554–559
8. Hadad G, Bassagasteguy L, Carrau RL, Mataza JC, Kassam A, Snyderman CH, Mintz A (2006) A novel reconstructive technique after endoscopic expanded endonasal approaches: vascular pedicle nasoseptal flap. Laryngoscope 116:1882–1886
9. Jane JA Jr, Han J, Prevedello DM, Jagannathan J, Dumont AS, Laws ER Jr (2005) Perspectives on endoscopic transsphenoidal surgery. Neurosurg Focus 19:E2
10. Kim DH, Hong YK, Jeun SS, Park YJ, Kim SW, Cho JH, Kim BY, Han S, Lee YJ, Hwang JH, Kim SW (2016) Intranasal volume changes caused by the endonasal endonasal transsphenoidal approach and its effects on nasal functions. PloS One 11:e0151531
11. Kiraz M, Gunaldi O, Tanriverdi O, Erdim I, Postalci LS, Tugcu B, Yazici MZ (2018) Comparison of sinonasal complications of microscopic and endoscopic approaches for transsphenoidal hypophysseal surgery: prospective study. Turk Neurosurg 28:915–922
12. Li A, Liu W, Cao P, Zheng Y, Bu Z, Zhou T (2017) Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary adenoma: a systematic review and meta-analysis. World Neurosurg 101:236–246
13. Li J, Ding W, Huang Z, Xie B, Li ZY (2019) Comparison of short-term outcomes between endoscopic and microscopic trans-sphenoidal surgery for the treatment of pituitary adenoma. J Craniocfac Surg 30:2421–2424
14. Little AS, Kelly DF, Milligan J, Griffiths C, Prevedello DM, Carrau RL, Rosseau G, Barkhoudarian G, Jahneke H, Chaloner C, Jelinek KL, Chapple K, White WL (2015) Comparison of sinonasal quality of life and health status in patients undergoing microscopic and endoscopic transsphenoidal surgery for pituitary lesions: a prospective cohort study. J Neurosurg 123:799–807
15. Little AS, Kelly DF, White WL, Gardner PA, Fernandez-Miranda JC, Chicoine MR, Barkhoudarian G, Chandler JP, Prevedello DM, Liebelt BD, Sfondouris J, Mayberg MR (2019) Results of a prospective multicenter controlled study comparing surgical outcomes of microscopic versus fully endoscopic transsphenoidal surgery for nonfunctioning pituitary adenomas: the
TranssphenoidalExtentofResection(TRANSSPHER)study. J Neurosurg 1–11
21. Pledger CL, Elzoghby MA, Oldfield EH, Payne SC, Jane JA Jr (2016) Prospectivecomparisonof sinonasal outcomes aftermicroscopic sublabial or endoscopic endonasal transsphenoidal surgery for nonfunctioning pituitary adenomas. J Neurosurg 125:323–333
22. Prajapati HP, Jain SK, Sinha VD (2018) Endoscopic versus microscopic pituitary adenoma surgery: an institutional experience. Asian J Neurosurg 13:217–221
23. Simal-Julián JA, Miranda-Lloret P, de San P, Román Mena L, Santromán-Álvarez P, García-Piñero A, Sanchis-Martín R, Botella-Asunció C, Kassam A (2020) Impact of multilayer vascularized reconstruction after skull base endoscopic endonasal approaches. J Neurol Surg B, Skull base 81:128–135
24. Strychowsky J, Nayan S, Reddy K, Farrokhyar F, Sommer D (2011) Purelyendoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas: systematic review. J Otolaryngol Head Neck Surg = Le Journal d’otolaryngologie et de chirurgie cervico-faciale 40:175–185
25. Wang S, Chen Y, Li J, Wei L, Wang R (2015) Olfactory function and quality of life following microscopic endonasal transsphenoidal pituitary surgery. Medicine 94:e465
26. Wang YY, Higham C, Kearney T, Davis JR, Trainer P, Gnanalingham KK (2012) Acromegaly surgery in Manchester revisited—the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol 76:399–406
27. Wang YY, Srirathan V, Tirr E, Kearney T, Gnanalingham KK (2011) Nasal symptoms following endoscopic transsphenoidal pituitary surgery: assessment using the General Nasal Patient Inventory. Neurosurg Focus 30:E12
28. Yu SY, Du Q, Yao SY, Zhang KN, Wang J, Zhu Z, Jiang XB (2018) Outcomes of endoscopic and microscopic transsphenoidal surgery on non-functioning pituitary adenomas: a systematic review and meta-analysis. J Cell Mol Med 22:2023–2027
29. Zador Z, Gnanalingham K (2013) Endoscopic transnasal approach to the pituitary—operative technique and nuances. Br J Neurosurg 27:718–726

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Charlie Osborne1,2 · Daniel Lewis2 · Ben Dixon3 · Carmela Caputo4 · Alison Magee5 · Kanna Gnanalingham2 · Yi Yuen Wang1,2,5
1 Department of Neurosurgery, St Vincent’s Hospital, Melbourne, VIC, Australia
2 Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
3 Department of Ear, Nose & Throat, Head and Neck Surgery, St Vincent’s Hospital, Melbourne, VIC, Australia
4 Department of Endocrinology, St Vincent’s Hospital, Melbourne, VIC, Australia
5 Keyhole Neurosurgery, Melbourne, VIC, Australia